- call +1-201-465-4211
- email sales@mrinsights.biz
Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors.
Scope of the Report:
The worldwide market for Parkinson’s Disease Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Parkinson’s Disease Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Abbvie, Inc.
Biogen, Inc.
Boehringer Ingelheim GmbH
F. Hoffman-La Roche
GlaxoSmithKline Plc.
H. Lundbeck A/S
Impax Labs, Inc.
Newron Pharmaceuticals SpA
Novartis AG
Orion Corporation
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
There are 15 Chapters to deeply display the global Parkinson’s Disease Therapeutics market.
Chapter 1, to describe Parkinson’s Disease Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Parkinson’s Disease Therapeutics, with sales, revenue, and price of Parkinson’s Disease Therapeutics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Parkinson’s Disease Therapeutics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Parkinson’s Disease Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Parkinson’s Disease Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Parkinson’s Disease Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Oral
1.2.2 Transdermal
1.2.3 Subcutaneous
1.2.4 Intestinal Infusion
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Abbvie, Inc.
2.1.1 Business Overview
2.1.2 Parkinson’s Disease Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbvie, Inc. Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Biogen, Inc.
2.2.1 Business Overview
2.2.2 Parkinson’s Disease Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Biogen, Inc. Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Boehringer Ingelheim GmbH
2.3.1 Business Overview
2.3.2 Parkinson’s Disease Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 F. Hoffman-La Roche
2.4.1 Business Overview
2.4.2 Parkinson’s Disease Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 GlaxoSmithKline Plc.
2.5.1 Business Overview
2.5.2 Parkinson’s Disease Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GlaxoSmithKline Plc. Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 H. Lundbeck A/S
2.6.1 Business Overview
2.6.2 Parkinson’s Disease Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Impax Labs, Inc.
2.7.1 Business Overview
2.7.2 Parkinson’s Disease Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Impax Labs, Inc. Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Newron Pharmaceuticals SpA
2.8.1 Business Overview
2.8.2 Parkinson’s Disease Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Novartis AG
2.9.1 Business Overview
2.9.2 Parkinson’s Disease Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Novartis AG Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Orion Corporation
2.10.1 Business Overview
2.10.2 Parkinson’s Disease Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Orion Corporation Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Teva Pharmaceutical Industries Ltd.
2.11.1 Business Overview
2.11.2 Parkinson’s Disease Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 UCB S.A.
2.12.1 Business Overview
2.12.2 Parkinson’s Disease Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 UCB S.A. Parkinson’s Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Parkinson’s Disease Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Parkinson’s Disease Therapeutics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Parkinson’s Disease Therapeutics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Parkinson’s Disease Therapeutics Manufacturer Market Share in 2017
3.3.2 Top 6 Parkinson’s Disease Therapeutics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Parkinson’s Disease Therapeutics Market Analysis by Regions
4.1 Global Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Regions
4.1.1 Global Parkinson’s Disease Therapeutics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Parkinson’s Disease Therapeutics Revenue and Market Share by Regions (2013-2018)
4.2 North America Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
4.3 Europe Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
4.5 South America Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
5 North America Parkinson’s Disease Therapeutics by Countries
5.1 North America Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Countries
5.1.1 North America Parkinson’s Disease Therapeutics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Parkinson’s Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
5.2 United States Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
5.3 Canada Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
5.4 Mexico Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
6 Europe Parkinson’s Disease Therapeutics by Countries
6.1 Europe Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Countries
6.1.1 Europe Parkinson’s Disease Therapeutics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Parkinson’s Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
6.3 UK Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
6.4 France Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
6.5 Russia Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
6.6 Italy Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Parkinson’s Disease Therapeutics by Countries
7.1 Asia-Pacific Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Parkinson’s Disease Therapeutics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Parkinson’s Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
7.2 China Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
7.3 Japan Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
7.4 Korea Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
7.5 India Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
8 South America Parkinson’s Disease Therapeutics by Countries
8.1 South America Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Countries
8.1.1 South America Parkinson’s Disease Therapeutics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Parkinson’s Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
8.3 Argentina Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
8.4 Colombia Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Parkinson’s Disease Therapeutics by Countries
9.1 Middle East and Africa Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Parkinson’s Disease Therapeutics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Parkinson’s Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
9.3 UAE Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
9.4 Egypt Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
9.5 Nigeria Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
9.6 South Africa Parkinson’s Disease Therapeutics Sales and Growth Rate (2013-2018)
10 Global Parkinson’s Disease Therapeutics Market Segment by Type
10.1 Global Parkinson’s Disease Therapeutics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Parkinson’s Disease Therapeutics Sales and Market Share by Type (2013-2018)
10.1.2 Global Parkinson’s Disease Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Oral Sales Growth and Price
10.2.1 Global Oral Sales Growth (2013-2018)
10.2.2 Global Oral Price (2013-2018)
10.3 Transdermal Sales Growth and Price
10.3.1 Global Transdermal Sales Growth (2013-2018)
10.3.2 Global Transdermal Price (2013-2018)
10.4 Subcutaneous Sales Growth and Price
10.4.1 Global Subcutaneous Sales Growth (2013-2018)
10.4.2 Global Subcutaneous Price (2013-2018)
10.5 Intestinal Infusion Sales Growth and Price
10.5.1 Global Intestinal Infusion Sales Growth (2013-2018)
10.5.2 Global Intestinal Infusion Price (2013-2018)
11 Global Parkinson’s Disease Therapeutics Market Segment by Application
11.1 Global Parkinson’s Disease Therapeutics Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Parkinson’s Disease Therapeutics Market Forecast (2018-2023)
12.1 Global Parkinson’s Disease Therapeutics Sales, Revenue and Growth Rate (2018-2023)
12.2 Parkinson’s Disease Therapeutics Market Forecast by Regions (2018-2023)
12.2.1 North America Parkinson’s Disease Therapeutics Market Forecast (2018-2023)
12.2.2 Europe Parkinson’s Disease Therapeutics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Parkinson’s Disease Therapeutics Market Forecast (2018-2023)
12.2.4 South America Parkinson’s Disease Therapeutics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Parkinson’s Disease Therapeutics Market Forecast (2018-2023)
12.3 Parkinson’s Disease Therapeutics Market Forecast by Type (2018-2023)
12.3.1 Global Parkinson’s Disease Therapeutics Sales Forecast by Type (2018-2023)
12.3.2 Global Parkinson’s Disease Therapeutics Market Share Forecast by Type (2018-2023)
12.4 Parkinson’s Disease Therapeutics Market Forecast by Application (2018-2023)
12.4.1 Global Parkinson’s Disease Therapeutics Sales Forecast by Application (2018-2023)
12.4.2 Global Parkinson’s Disease Therapeutics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Parkinson’s Disease Therapeutics Picture
Table Product Specifications of Parkinson’s Disease Therapeutics
Figure Global Sales Market Share of Parkinson’s Disea
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
